Wells Fargo’s ZyVersa Therapeutics ZVSA Stock Holding History

Wells Fargo’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1	Closed	-$9	–	7552
2024 Q1	$9	Hold	1	–	–	﹤0.01%	7316
2023 Q4	$9	Buy	+1	New	+$28	﹤0.01%	7415
2023 Q3	–	Hold	0	–	–	–	7187
2023 Q2	–	Hold	0	–	–	–	7229
2023 Q1	–	Hold	0	–	–	–	7094

Other funds holding ZVSA

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wells Fargo's ZVSA Position: Q2 2024 in Review

Wells Fargo sold out of ZyVersa Therapeutics (ZVSA) in Q2 2024, closing a stake of 1 share — an estimated $9 sold.

Wells Fargo first reported a position in ZVSA in Q4 2023 and held it in 2 quarters. The position peaked at $9 in Q1 2024. 4 funds tracked by Wall St. Rank hold ZVSA as of Q2 2024.

Wells Fargo reported no remaining ZyVersa Therapeutics position as of Q2 2024 after selling out during the quarter.
Wells Fargo sold 1 ZyVersa Therapeutics share in Q2 2024, an estimated $9.
Wells Fargo first reported a position in ZyVersa Therapeutics in Q4 2023 and held it in 2 quarters.
Wells Fargo's ZyVersa Therapeutics position peaked at $9 in Q1 2024.
4 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.